Sangamo Therapeutics Q1 2024 GAAP EPS $(0.27) Misses $(0.22) Estimate, Sales $481.000K Miss $6.654M Estimate
Sangamo Therapeutics Q1 2024 GAAP EPS $(0.27) Misses $(0.22) Estimate, Sales $481.000K Miss $6.654M Estimate
Sangamo Therapeutics 2024 年第一季度公認會計准則每股收益 (0.27) 未達到預期 (0.22) 美元，銷售額爲 481.000 萬美元，未達預期 66.54 萬美元
Sangamo Therapeutics (NASDAQ:SGMO) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.22) by 22.73 percent. This is a 325 percent decrease over earnings of $0.12 per share from the same period last year. The company reported quarterly sales of $481.000 thousand which missed the analyst consensus estimate of $6.654 million by 92.77 percent. This is a 99.70 percent decrease over sales of $157.957 million the same period last year.
Sangamo Therapeutics（納斯達克股票代碼：SGMO）公佈的季度虧損爲每股0.27美元，比分析師普遍預期的0.22美元（0.22美元）低22.73％。與去年同期的每股收益0.12美元相比，下降了325％。該公司公佈的季度銷售額爲48.1萬美元，比分析師共識估計的665.4萬美元低92.77％。這比去年同期的1.57957億美元的銷售額下降了99.70％。